Leukocyte adhesion deficiency disrupts leukocyte adhesion and migration, impacting margination and chemotaxis while leaving the intracellular killing mechanisms functional. This nuance helps explain why infection control can persist once leukocytes reach infected tissue, even when movement is compromised.

Multiple Choice

In patients with leukocyte adhesion deficiency (LAD), which function remains intact despite the defect?

In leukocyte adhesion deficiency (LAD), a primary defect occurs in the ability of leukocytes to adhere to blood vessel endothelium, which is crucial for their migration into tissues during an immune response. This defect is primarily caused by mutations affecting the integrins on the surface of leukocytes. While phagocytosis, chemotaxis, and margination are all processes that are significantly affected by this adhesion defect, antibacterial activity, or bacterial killing, remains largely intact. This is because once leukocytes are in the site of infection, they can still use their intracellular mechanisms to kill bacteria. The problem primarily arises during the initial steps of the immune response—when leukocytes attempt to exit the bloodstream and reach the site of infection. Thus, despite the difficulties faced in adhering and migrating to areas of infection due to the defect, the actual process of killing bacteria is still functional, allowing for some level of immune response to continue. This distinction highlights that LAD primarily affects the movement and localization of immune cells rather than their innate ability to eliminate pathogens once they are present in tissues.

Leukocyte adhesion deficiency (LAD) is one of those conditions that sounds like a mouthful but reveals a simple, stubborn truth: the immune system runs on both movement and muscle. In LAD, the trouble isn’t that white blood cells can’t kill bacteria once they meet them. The hitch is getting to the battlefield in the first place. Think of it as a city’s guard force that can still fight once inside town walls, but has trouble threading through the gates when a siren goes off.

What LAD actually does

To understand the punchline, it helps to zoom out a little and map the usual journey of an immune cell. Normally, when a microbe invades, circulating leukocytes—neutrophils, for instance—hourglass through the bloodstream, find the injured or infected site, and squeeze through the vessel wall to reach the soldiers of infection. That squeeze, that exit through the capillary walls, relies on a set of adhesive molecules on the surface of leukocytes. These integrins act like tiny grappling hooks, grabbing endothelial cells, slowing the leukocytes, and guiding them toward the inflamed tissue. It’s a well-choreographed dance: rolling along the endothelium, firm adhesion, diapedesis (the fancy word for passing through the vessel wall), and then full-on phagocytosis if bacteria are present.

In LAD, that first critical step—adherence and exit—gets bungled. The underlying defect is in the integrins on leukocytes. Without a solid grip, the cells don’t arrest and don’t migrate efficiently into tissues where they’re needed. So, despite a normal or even robust circulating pool of immune cells, their ability to respond at sites of infection is blunted. It’s like having a border patrol that’s plentiful, but the gates are stuck, and the sentries never reach the town square on time.

A quick mental model: the traffic analogy

Picture a city struck by a sudden emergency. The ambulances (your leukocytes) are on the highway (the bloodstream). Normally, when a call comes in, they hit the exits, pass through checkpoints, and flood the affected neighborhood. In LAD, the gates refuse to cooperate. The ambulances can still navigate rough terrain and fight fires once they’re inside, but they can’t exit the highway efficiently. The result is a delayed or insufficient immune presence at the site of infection. The body still has tools—enzymes inside phagocytes, reactive oxygen species, antimicrobial peptides—but if the units can’t reach the intruder, the overall defense takes a hit.

Where the silver lining sits: killing can still happen

Here’s the essential point that sometimes gets glossed over: the intrinsic killing machinery inside leukocytes remains functional. Once a leukocyte actually gets to an infection site, it can still perform phagocytosis and enzymatic microbial killing using the intracellular arsenal. The issue isn’t the “how” of killing; it’s the “whether they arrive.” So, in LAD, bacterial killing is largely preserved in terms of the cellular machinery, but reaching bacteria inside tissues is where the problem lies.

That distinction matters for clinical intuition. If you imagine a two-part process—first, mobilization and migration; second, execution of antimicrobial killing—the deficit sits squarely in the first part. The second part still works, to a meaningful degree, because the phagolysosome pathway, respiratory burst, and lysosomal enzymes can do their job once the leukocytes are where they should be.

Why this distinction matters for understanding infections

This nuance helps explain why patients with LAD can have recurrent bacterial infections, even when their leukocytes aren’t deficient in number or in some basic functional readouts. The persistent theme is the bottleneck at the entry point to infected tissues. You might see extensive infections in mucosal surfaces, skin, and soft tissues, especially where rapid movement of immune cells to the site is essential. The infections can be unusually severe or protracted because the initial containment and containment acceleration are compromised.

That said, the body’s innate defense isn’t completely broken. The inflammatory signals that recruit cells to the scene can still be generated, and once leukocytes reach the site, they rally with their usual gusto. The paradox is fascinating: part of the immune system is perfectly capable, while another part—the logistics of arrival—lets it down. It’s a reminder that immune defense is as much about where cells show up as what they’re capable of once they’re there.

What clinical clues help you spot LAD (without turning this into a scavenger hunt)

  • Recurrent bacterial infections that are unusually persistent or severe, often starting in early childhood.

  • Poor wound healing and mucosal infections, with slow resolution.

  • Delayed separation of the umbilical cord in newborns can be an early hint.

  • A tendency toward neutrophilia in blood tests, because cells are produced but don’t migrate efficiently into tissues.

A note on the underlying biology

The integrins involved—like LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18)—are the anchors in the migration process. When these anchors don’t function properly, leukocytes just can’t form the tight adhesive interactions needed for diapedesis. It’s not that phagocytosis is broken, nor chemotaxis per se once a leukocyte has left the bloodstream; it’s the critical step of getting to the battlefield in the first place that’s compromised. The result is a mismatch between the immune system’s potential for action and the reality of its access to the site of infection.

Chemotaxis versus migration: keeping the threads straight

Chemotaxis is the guided movement toward chemical signals, like chemokines released by an infected tissue. It’s an essential component of getting leukocytes to the right neighborhood. In LAD, the defect is not primarily in the chemical sensing itself, but in the actual ability to adhere to and transmigrate through the vessel wall. So, you can still have signals pulling leukocytes in that direction, but the “doors” to the tissue are effectively jammed. The cells may follow gradients inside the vasculature, but they don’t exit readily to the tissue. That subtlety is easy to miss if you focus only on the “follow the signal” part and forget the gatekeeping role of adhesion.

A practical, relatable analogy

Think of leukocytes as firefighters. The fire truck leaves the station (the blood) and travels to the scene (the infected tissue). The route and the turnout are important, but so are the doors to the building. In LAD, the doors are locked or misaligned. The crew can smash through the door if they get a chance, and once inside the building, they can put out flames and clean up debris with their hoses and gear. Themis at the doorstep slows everything down. That’s why the real Achilles heel is the migration step—not the firefighting tools themselves.

What this means for treatment thinking (without going into clinical protocols)

  • The core issue to manage isn’t the bacteria in isolation, but the host’s ability to mobilize immune cells to the right place quickly.

  • Infection control measures still matter, because preventing infection in the first place buys the immune system time to rally.

  • Supportive care often focuses on mitigating complications and supporting barriers (skin integrity, wound care) since the barrier function and initial defense are where the bottleneck lies.

  • In some forms of LAD, hematopoietic stem cell transplantation has been explored as a curative route because it can replace the defective immune system with one that has proper adhesion molecules. It’s not a casual option, but it demonstrates the underlying principle: fix the gateway, and the troops can do their job.

A note on the human story behind the science

Behind the immunology jargon are real people with real experiences. A child who keeps getting skin infections, a family balancing care with everyday life, clinicians who read headlines about genetics and lab results and translate them into steps on the ground. The beauty of understanding LAD at a conceptual level is that it makes the human story legible: why a seemingly routine fever or skin sore can become a bigger deal when the body’s “gate” to the infection site isn’t functioning as it should.

Relating to other immune mysteries

LAD sits at an interesting intersection with other immune disorders. For instance, in conditions where phagocytes can’t ingest or kill bacteria, the problem is downstream of migration. In LAD, the “downstream” processes work, but the upstream logistics fail. It’s a helpful reminder that the immune response is a chain, and when one link—like the gateway—stumbles, the whole chain’s effectiveness wobbles.

Clinical takeaways that stick

  • In LAD, the main defect is enforcement of leukocyte adhesion and migration, not the bactericidal machinery.

  • Bacterial killing, once leukocytes reach the site, remains functional. That contrast helps explain why infections can be persistent but not necessarily due to defects in intracellular killing capacity.

  • Management is as much about preventing infection and supporting barrier integrity as it is about addressing any invasive pathogens directly.

  • The story of LAD underscores a broader theme in medicine: the difference between capability and accessibility. A powerful tool is only as good as its reach.

Final reflections: the balance between movement and might

If you take away one thread from this, let it be this: the immune system functions like a well-oiled team, with roles that build on each other. The movers—the leukocytes—need to reach the scene to apply their skills. In LAD, the problem isn’t the team’s skill at fighting; it’s the doors, and the route, and the checkpoint that let them be where they’re needed when danger calls. Once inside, the fight remains fierce, precise, and effective. That subtle distinction—where the action happens more than what action is possible—gives LAD its unique character and helps clinicians approach it with the right mindset: guard the gates, but never underestimate the power of a cell that finally makes it to the front lines.